The Treg cells obtained from aGVHD and non-GVHD patients were isolated before the starting of specific treatments, such as anti-CD25 or anti-CD52 monoclonal antibodies and mesenchymal stem cells (MSCs), except for the routinely prophylactic application of cyclosporine or tacrolimus after transplantation. The gene discussed is CD52; the disease is graft versus host disease.